Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Boosted by Swiss National Bank

Swiss National Bank lifted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 7.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 124,600 shares of the biotechnology company’s stock after acquiring an additional 8,400 shares during the period. Swiss National Bank’s holdings in Blueprint Medicines were worth $10,868,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after acquiring an additional 729,055 shares during the last quarter. State Street Corp grew its position in shares of Blueprint Medicines by 16.2% during the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Blueprint Medicines by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock worth $136,942,000 after acquiring an additional 20,703 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Blueprint Medicines by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company’s stock worth $52,716,000 after acquiring an additional 7,165 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in Blueprint Medicines by 161.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after buying an additional 306,079 shares in the last quarter.

Insider Transactions at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the transaction, the director now owns 157,557 shares in the company, valued at approximately $16,114,929.96. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,334 shares of company stock valued at $3,103,512 over the last three months. 4.21% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BPMC has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Scotiabank initiated coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Stephens reiterated an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.95.

Blueprint Medicines Price Performance

BPMC stock opened at $88.47 on Friday. The firm has a 50-day moving average of $99.45 and a two-hundred day moving average of $93.92. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $5.65 billion, a PE ratio of -81.92 and a beta of 0.58. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.